Licensing committee reviews draft AB 1503 policy for non‑resident pharmacies, stakeholders urge clearer language and better outreach

The California State Board of Pharmacy Licensing Committee on April 15 reviewed a draft policy statement aimed at guiding non‑resident pharmacies through changes made by Assembly Bill 1503 (Burman, ch. 196, 2025).

The committee chair, Sano, described the statement as an educational document to clarify the board’s priorities for compliance and enforcement. The statement is intended to accompany statutory changes that became effective Jan. 1, 2026, with some implementation delayed to July 1 to allow licensees more time to comply.

Why it matters: AB 1503 introduced multiple changes to how non‑resident pharmacies must operate in relation to California patients. Stakeholders told the committee that vague phrasing in the draft could create uncertainty about what the board will enforce, potentially prompting smaller pharmacies to limit services to California residents.

Industry groups asked the committee to reduce open‑ended wording (for example, phrases such as “including, but not limited to”) that could be read as creating enforceable obligations beyond statute or regulation. “Open‑ended examples create unpredictable enforcement, overengineering of compliance and reduced patient access,” Sarah Polo of the California Retailers Association and California Community Pharmacy Coalition said during public comment.

Committee members also discussed specific provisions that brought practical questions. Jesse asked whether the requirement that a designated pharmacist in charge (PIC) be “employed and actively working at the non‑resident pharmacy” might create confusion about whether ‘‘actively working’’ requires physical presence at the dispensary. Chair Sano said staff and board counsel would explore clearer wording.

Public commenters stressed operational concerns. Dr. Courtney Sulland, a mail‑order pharmacist, said delays collecting hard‑copy verifications from other states made it difficult for some practitioners to complete California licensure in time for the July effective date. “I can’t make any progress because other boards are unresponsive,” she said, describing repeated requests for paper verification forms that were not returned.

Staff response and next steps: Members recommended several near‑term actions that do not require immediate rulemaking: (1) refine drafting to reduce ambiguous phrasing where possible; (2) prepare a focused landing page with centralized guidance and links to frequently used statutory references; and (3) coordinate outreach and additional exam administrations so applicants have realistic opportunities to meet new licensing requirements. The committee signaled it would forward a refined policy statement to the full board for formal approval in the board meeting scheduled later in April.

What the committee approved: On a separate procedural item, the committee unanimously approved minutes from its Jan. 8, 2026 meeting. The licensing committee did not adopt regulatory text for the policy statement at this meeting; members and staff agreed further edits and stakeholder input would precede formal board action.

Outlook: The committee asked staff to (a) work with board counsel on clarification of PIC and related PIC‑training materials, (b) develop a clear web landing page and possible FAQ additions for non‑resident pharmacies, and (c) monitor reports of licensure delays and report back. The board emphasized its primary mission of consumer protection while flagging an intent to avoid unnecessary interruptions to patients’ medication access.